Janus Henderson Group PLC Rotates From Mega-Cap AI To Healthcare Depth

Janus Henderson’s biggest buys are all about deepening exposure to long-duration growth that doesn’t solely depend on one AI narrative. The AstraZeneca entry at 1.15% is a statement: they’re willing to pay up near current levels (gain_vs_avg_buy_pct at only 4.4%) for a diversified, late-stage pipeline in oncology, respiratory, and immunology that can compound outside the hype cycle.

The rest of the healthcare complex shows similar intent. They scale Madrigal Pharmaceuticals by +27.4% and BridgeBio by +19.8%, while pushing Vaxcyte up +23.8% and Boston Scientific +31.0%. Layer that onto increases in Johnson & Johnson, AbbVie, UnitedHealth, argenx, and a larger Boston Scientific footprint, and you get a clear thesis: pay for clinically validated platforms in metabolic, cardiovascular, rare disease, and devices, not speculative binary biotech.

On the infrastructure side, the 4,358.6% ramp in GE Vernova to $1.32B is the clearest new macro bet. It ties neatly into a +19.5% add to Micron and a +10.9% add to ON Semiconductor: AI’s marginal demand ultimately runs through power, memory bandwidth, and industrial electronics. They complement that with incremental buys in Lam Research, Eaton, and JB Hunt, plus a +25.2% step-up in TotalEnergies and a modest Chevron presence, effectively framing an energy-and-logistics spine under their growth book.

Consumer and payments adds look more selective and quality-driven. They boost Visa by +33.1% and Netflix by +12.2%, and increase LPL Financial by +8.6% and Liberty’s F1 tracking stock, but there’s no broad reach for cyclicals. The bet is clear: resilient fee pools and scalable platforms, not generic reopening or rate plays.

The funding sources tell you what Janus Henderson thinks has already done its job. Microsoft, still 4.37% of the book, is cut by -10.9%, taking out about $1.08B of exposure; Amazon is trimmed -14.7% for roughly $1.03B; Oracle is down -17.1%. These aren’t thesis breaks so much as harvesting oversized winners where multiples are full and the AI halo is well understood.

Broadcom’s -4.3% trim, despite being a 2.96% position, fits the same pattern: lighten the AI toll booths once consensus has fully caught on, while keeping Nvidia essentially intact (+0.2%). Alphabet’s GOOG line is down -3.3% even as they add +20.9% to GOOGL – effectively rebalancing share classes and marginally reducing total Alphabet exposure.

Outside software, they’re quietly de-risking in expensive quality growth. Booking is down -15.3%, Mastercard -13.2%, Progressive -13.1%, and J.B. Hunt only inches higher despite strong performance. In healthcare, Revolution Medicines is cut -20.6% and Vertex -4.1%, even as capital is redirected into broader pipelines and de-risked therapies like AstraZeneca, AbbVie, and Boston Scientific.

The pattern is consistent: trim where gains vs average cost are triple-digit and crowding is high, especially in mega-cap tech, high-multiple quality compounders, and more speculative oncology names. The proceeds are recycled into a wider set of growth drivers with more room for positive surprise and less dependence on one or two narratives.

By sector, Janus Henderson is nudging, not flipping the book. Technology slips from 60.77% to 58.61% of the top-50, still the dominant pillar, but the marginal dollar is pointed elsewhere. Trims in Microsoft, Amazon, Alphabet, Broadcom, Oracle, Intuit, and Flex more than offset adds to Meta, Micron, ON, DoorDash, and Lam Research.

The real rotation is into healthcare, which climbs from 14.15% to 16.61%. This isn’t one stock; it’s a broad-based build-out across big pharma (Eli Lilly, AstraZeneca, AbbVie, Johnson & Johnson), managed care (UnitedHealth), medtech (Boston Scientific), and high-conviction biotech platforms (argenx, Madrigal, BridgeBio, Vaxcyte). That mix gives them both defensiveness and optionality after a negative quarter.

They also create a larger “infrastructure and energy transition” sleeve almost by stealth. Industrials edge down slightly to 4.02%, but that masks a sharp repositioning: Howmet is trimmed, while GE Vernova explodes higher and Eaton and JB Hunt are topped up. Energy rises modestly from 1.69% to 1.73% as they add TotalEnergies and trim Chevron, favoring more integrated, transition-ready exposure.

Consumer Discretionary eases from 9.66% to 8.54%, with Amazon and Booking trims outweighing a Netflix add and small APi Group increase. Finance ticks down from 3.97% to 3.82% after cuts in Progressive and ICE despite more LPL. Put differently: away from core AI and select platforms like Visa and Netflix, they are unwilling to lean hard into broad consumer or financial cyclicality right now.

Taken together, this quarter looks like Janus Henderson re-engineering its growth engine rather than abandoning it. The fund is anchoring on AI-scale platforms plus the ecosystems that enable and benefit from them — Nvidia, Meta, Micron, ON, Lam, Eaton, GE Vernova — while progressively shifting incremental risk into healthcare innovation and select fee-based franchises in payments and wealth.

If AI and cloud spending keep compounding, they are still heavily exposed through Nvidia, Alphabet, Microsoft, Amazon, and the semi stack, even after trims. But if the market starts to balk at AI multiples or growth expectations, the expanded healthcare allocation, medtech adds, and energy-infrastructure plays provide a second leg of secular growth that is less correlated with software P/E compression.

Going forward, expect more of this quiet rotation underneath a stable tech headline weight: trims around mature, crowded software and mega-cap internet, plus adds in second-derivative names in memory, grid, and healthcare platforms where pipeline data, not narrative, is the main driver. The -9.96% quarter hasn’t pushed them into defense; it has pushed them into diversified, multi-engine growth that can earn through a wider range of macro and sentiment regimes.

For readers tracking style, this is still a growth manager — but one that’s clearly transitioning from a “mega-cap AI and friends” book into a barbell of platform tech and less-loved secular growth pockets. The next few quarters will show whether those mid-cap healthcare and infrastructure bets start climbing the ranks into the new core.